Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...
Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...
Moments after Regeneron CEO Len Schleifer scolded analysts for asking too many questions about the disappointing sales of eye ...
Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...
Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter ...
ABC 7 New York on MSN12d
Passionate Long Island senior selected as Regeneron finalist for pancreatic cancer researchEmma Wen, a senior at Great Neck North High School, is researching more effective ways to fight pancreatic cancer.
MAIA Biotechnology (MAIA) announced updated data from its THIO-101 pivotal Phase 2 clinical trial evaluating its lead clinical candidate, THIO, ...
Precision medicine is revolutionizing healthcare, and these genomic stocks are leading the way. Therefore, as this sector ...
MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer ...
The Lipodystrophy market growth is driven by factors like increase in the prevalence of Lipodystrophy, investments in research and development, entry of emerging therapies during the study period 2020 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback